TIDEL-Ii: First-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Blood

Volumn 125, Issue 6, 2015, Pages 915-923

  Yeung, David T ^a,b,c   Osborn, Michael P ^a,b,c   White, Deborah L ^b,c,d   Branford, Susan ^a,b,e   Braley, Jodi ^a   Herschtal, Alan ^f   Kornhauser, Michael ^f   Issa, Samar ^c,g   Hiwase, Devendra K ^a,b,c   Hertzberg, Mark ^c,h,i   Schwarer, Anthony P ^c,j   Filshie, Robin ^c,k   Arthur, Christopher K ^c,l   Kwan, Yiu Lam ^c,m   Trotman, Judith ^c,i,m   Forsyth, Cecily J ^c,n   Taper, John ^c,i,o   Ross, David M ^a,b,c   Beresford, Jennifer ^f   Tam, Constantine ^c,f   Mills, Anthony K ^e,p   Grigg, Andrew P ^c,q   Hughes, Timothy P ^a,b,d   more..

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Australasian Leukaemia and Lymphoma Group   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g MIDDLEMORE HOSPITAL   (New Zealand)

^h PRINCE OF WALES HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j BOX HILL HOSPITAL   (Australia)

^k ST VINCENT S HOSPITAL   (Australia)

^l ROYAL NORTH SHORE HOSPITAL   (Australia)

^m Department of Microbiology and Infectious Diseases   (Australia)

ⁿ GOSFORD HOSPITAL   (Australia)

^o NEPEAN HOSPITAL   (Australia)

^p PRINCESS ALEXANDRA HOSPITAL   (Australia)

^q UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; LIVER ENZYME; NILOTINIB; PANCREAS ENZYME; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTHRALGIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CYTOPENIA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN ALLERGY; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922365224     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-590315     Document Type: Article

References (61)

1. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009; 114(22). Abstract 1126.
2. Druker BJ, Guilhot F, O'Brien SG, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23): 2408-2417.
3. Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003; 120(6): 990-999.
4. Yeung DT, Branford S. Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays? Hematology (Am Soc Hematol Educ Program). 2012; 2012: 111-114.
5. Hughes TP, Hochhaus A, Branford S, et al.; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010; 116(19): 3758-3765.
6. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26(20): 3358-3363.
7. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11(9): 3425-3432.
8. Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009; 113(25): 6315-6321.
9. Hanfstein B, Müller MC, Hehlmann R, et al.; SAKK; German CML Study Group. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012; 26(9): 2096-2102.
10. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3): 232-238.
11. Baccarani M, Cortes J, Pane F, et al.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35): 6041-6051.
12. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123(9): 1353-1360.
13. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014; 123(4): 494-500.
14. Hughes TP, Branford S, White DL, et al.; Australasian Leukaemia and Lymphoma Group. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008; 112(10): 3965-3973.
15. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood. 2007; 109(8): 3496-3499.
16. Larson RA, Druker BJ, Guilhot F, et al.; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008; 111(8): 4022-4028.
17. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872-884.
18. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28(3): 424-430.
19. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999; 107(3): 587-599.
20. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med. 2006; 125: 69-92.
21. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108(1): 28-37.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446): 496-509.
23. Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011; 25(9): 1433-1438.
24. Guilhot J, Baccarani M, Clark RE, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012; 119(25): 5963-5971.
25. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010; 24(10): 1719-1724.
26. Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013; 121(19): 3818-3824.
27. Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26(10): 2172-2175.
28. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 2006; 20(4): 664-670.
29. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012; 26(10): 2197-2203.
30. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119(5): 1123-1129.
31. Hochhaus A, Saglio G, Larson RA, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013; 121(18): 3703-3708.
32. Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology (Am Soc Hematol Educ Program). 2013; 2013: 168-175.
33. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011; 86(7): 533-539.
34. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013; 27(6): 1316-1321.
35. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013; 27(6): 1310-1315.
36. Latagliata R, Breccia M, Fava C, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013; 31(2): 103-109.
37. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125(17): 2128-2137.
38. Preudhomme C, Guilhot J, Nicolini FE, et al.; SPIRIT Investigators; France Intergroupe des Leucémies Myélöides Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363(26): 2511-2521.
39. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon - a in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011; 29(12): 1634-1642.
40. Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013; 121(24): 4867-4874.
41. Deininger MW, Kopecky KJ, Radich JP, et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014; 164(2): 223-232.
42. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12(9): 841-851.
43. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized highdose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014; 32(5): 415-423.
44. Etienne G, Dulucq S, Nicolini FE, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014; 99(3): 458-464.
45. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013; 122(4): 515-522.
46. Mahon FX, Réa D, Guilhot J, et al.; Intergroupe Français des Leucémies Myélöides Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029-1035.
47. Hughes TP, Lipton JH, Spector N, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after longterm imatinib. Blood. 2014; 124(5): 729-736.
48. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984; 63(4): 789-799.
49. Hasford J, Pfirrmann M, Hehlmann R, et al.; Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90(11): 850-858.
50. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011; 118(3): 686-692.
51. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol. 2007; 25(28): 4445-4451.
52. Marin D, Gabriel IH, Ahmad S, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 2012; 26(2): 296-302.
53. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 2005; 106(7): 2520-2526.
54. White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of longterm outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010; 28(16): 2761-2767.
55. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood. 2005; 106(3): 1133-1134.
56. McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD341 cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2010; 115(2): 315-325.
57. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011; 117(24): 6660-6668.
58. Soliera AR, Mariani SA, Audia A, et al. Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia. 2012; 26(7): 1555-1563.
59. Kok CH, Watkins DB, Leclercq T, D'Andrea RJ, Hughes TP, White DL. Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation. Leukemia. 2013; 27(6): 1427-1430.
60. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18(4): 521-528.
61. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013; 121(22): 4439-4442.